| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/04/2011 | US20110190194 Preparation and composition of inter-alpha proteins from blood |
| 08/04/2011 | US20110189318 Methods for enhancing the expression of intracellular redox-associated factors |
| 08/04/2011 | US20110189315 Plant extract and pufa combinations |
| 08/04/2011 | US20110189306 COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES |
| 08/04/2011 | US20110189305 Treatment of lung cancer |
| 08/04/2011 | US20110189288 Diethylstilbestrol dosage form and methods of treatment |
| 08/04/2011 | US20110189268 Inhibition of Placenta Growth Factor (PLGF) Mediated Metastasis and/or Angiogenesis |
| 08/04/2011 | US20110189265 Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias |
| 08/04/2011 | US20110189263 Peptides that target dorsal root ganglion neurons |
| 08/04/2011 | US20110189252 Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases |
| 08/04/2011 | US20110189239 Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same |
| 08/04/2011 | US20110189238 Use of a soluble form of hla-g in the treatment of abnormal b-lymphocyte proliferation |
| 08/04/2011 | US20110189237 Therapeutic Agent for Malignant Mesothelioma and Immunostimulant |
| 08/04/2011 | US20110189235 Adipogenic Adenoviruses As A Biomarker For Disease |
| 08/04/2011 | US20110189234 Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles |
| 08/04/2011 | US20110189214 Cdca1 epitope peptides and vaccines containing the same |
| 08/04/2011 | US20110189213 Mybl2 epitope peptides and vaccines containing the same |
| 08/04/2011 | US20110189212 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders |
| 08/04/2011 | US20110189209 Fold-back diabody diphtheria toxin immunotoxin and methods of use |
| 08/04/2011 | US20110189206 Antibody Targeting Through a Modular Recognition Domain |
| 08/04/2011 | US20110189205 Methods of treating cancer using an agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor |
| 08/04/2011 | US20110189204 Treatment of Disease with Proteasone Inhibitors |
| 08/04/2011 | US20110189203 Immunoglobulin constructs |
| 08/04/2011 | US20110189202 Compositions comprising soluble cd84 or anti-cd84 antibodies and methods for diagnosing and treating b-cll |
| 08/04/2011 | US20110189195 Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase |
| 08/04/2011 | US20110189192 Novel compounds that are erk inhibitors |
| 08/04/2011 | US20110189189 Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
| 08/04/2011 | US20110189188 Novel gp96 derived peptides |
| 08/04/2011 | US20110189186 Affecting bone related conditions using cd68 blocking agents |
| 08/04/2011 | US20110189185 Method for Predicting Responsiveness to a Treatment With an Anti-HER2 Antibody |
| 08/04/2011 | US20110189179 Identification of Tumor-Associated Antigens for Diagnosis and Therapy |
| 08/04/2011 | US20110189175 Chronic lymphocytic leukemia prognosis and treatment |
| 08/04/2011 | US20110189173 PHOSPHORYLATED C-ErbB2 AS A SUPERIOR PREDICTIVE THERANOSTIC MARKER FOR THE DIAGNOSIS AND TREATMENT OF CANCER |
| 08/04/2011 | US20110189170 Chimeric Anti-VEGF-D Antibodies and Humanized Anti-VEGF-D Antibodies and Methods of Using the Same |
| 08/04/2011 | US20110189169 Combination of hgf inhibitor and pten agonist to treat cancer |
| 08/04/2011 | US20110189168 Antibody-induced apoptosis |
| 08/04/2011 | US20110189167 Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases |
| 08/04/2011 | US20110189159 Methods and compositions for protein delivery |
| 08/04/2011 | US20110189154 Applications For A New Class Of Enzymes: Sulfiredoxins |
| 08/04/2011 | US20110189141 Multiple target t cell receptor |
| 08/04/2011 | US20110189139 Hematopoietic Cell E-Selectin/L-Selectin Ligand Glycosylated CD44 Polypeptide |
| 08/04/2011 | US20110189131 Active variants of the il-18 binding protein and medical uses thereof |
| 08/04/2011 | US20110189130 Dihydropyrazolopyrimidinone derivatives |
| 08/04/2011 | US20110189128 Recombinant super-compound interferon |
| 08/04/2011 | US20110189125 Modulators of HSP70/DnaK Function and Methods of Use Thereof |
| 08/04/2011 | US20110189120 Aegyptin and uses thereof |
| 08/04/2011 | US20110189097 Use of WNT inhibitor to inhibit angiogenesis in the CNS |
| 08/04/2011 | US20110189095 Crkl targeting peptides |
| 08/04/2011 | US20110189093 Prostate specific membrane antigen antibodies and antigen binding fragments |
| 08/04/2011 | US20110189092 Polymer-agent conjugates, particles, compositions, and related methods of use |
| 08/04/2011 | US20110189087 TMPRSS4-Specific Human Antibody |
| 08/04/2011 | US20110189085 Antibody Therapy |
| 08/04/2011 | US20110189084 Method for Treating Liver Disorders with Receptor Associated Protein (RAP) Peptide-Fucosidase Inhibitor Conjugates |
| 08/04/2011 | US20110189083 Dock-and-Lock (DNL) Vaccines for Cancer Therapy |
| 08/04/2011 | US20110189082 Human gm-csf antigen binding proteins |
| 08/04/2011 | DE102010044870A1 Hemmung des Überlebens von Mundhöhlenkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of oral cancer by cyclohexenone from Antrodia camphorata |
| 08/04/2011 | DE102009041241A1 New heteroaromatic compounds are hypoxia-inducible factor inhibitors useful to treat and/or prevent e.g. cancer or tumor diseases, heart attack, arrhythmia, stroke, psoriasis, diabetic retinopathy, rheumatoid arthritis and polycythemia |
| 08/04/2011 | CA2788073A1 Di-substituted pyridine derivatives as anticancers |
| 08/04/2011 | CA2787784A1 Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| 08/04/2011 | CA2787590A1 Transformation plasmid |
| 08/04/2011 | CA2787407A1 5-alkynyl-pyrimidines |
| 08/04/2011 | CA2787396A1 5-alkynyl pyrimidines and their use as kinase inhibitors |
| 08/04/2011 | CA2787321A1 Pyrazolopyridine kinase inhibitors |
| 08/04/2011 | CA2787315A1 Pyrazolopyridine kinase inhibitors |
| 08/04/2011 | CA2786655A1 Radioimmunoconjugates that blind human cd37 and uses thereof |
| 08/04/2011 | CA2786509A1 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
| 08/04/2011 | CA2786438A1 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases |
| 08/03/2011 | EP2351852A1 RNA interference mediating small RNA molecules |
| 08/03/2011 | EP2351840A1 Polypeptides involved in immune response |
| 08/03/2011 | EP2351836A1 Double-stranded oligonucleotides |
| 08/03/2011 | EP2351777A1 Anti-muc1 antibody |
| 08/03/2011 | EP2351765A2 Oligonucleotide-containing pharmacological compositions and their use |
| 08/03/2011 | EP2351764A1 Trehalose compound, method for producing same, and pharmaceutical product containing the compound |
| 08/03/2011 | EP2351758A1 Metal complexes, a method for preparing same, radiopharmaceutical means based thereon |
| 08/03/2011 | EP2351757A1 Rapamycin carbonic ester analogues, pharmaceutical compositions, preparations and uses thereof |
| 08/03/2011 | EP2351743A1 Bicyclic compound |
| 08/03/2011 | EP2351730A1 Ethoxy diphenyl ethane derivates, preparation processes and uses thereof |
| 08/03/2011 | EP2351599A1 Method for producing dendritic cells |
| 08/03/2011 | EP2351586A1 Pharmaceutical compositions of active polypeptides for enhanced pharmacological activity through oral and parenteral administration |
| 08/03/2011 | EP2351584A1 Novel anti-IL 13 antibodies and uses thereof |
| 08/03/2011 | EP2351575A2 Novel uses of grs proteins or fragments thereof |
| 08/03/2011 | EP2351572A1 Agent having anti-helicobacter pylori activity |
| 08/03/2011 | EP2351571A1 Protein phosphatase inhibitor |
| 08/03/2011 | EP2351564A1 Methods of treating an inflammatory-related disease |
| 08/03/2011 | EP2351563A1 Agent for treatment of diabetes |
| 08/03/2011 | EP2351561A2 Novel methods and compositions for alleviating pain |
| 08/03/2011 | EP2350664A1 Treatment of cancer using hypoxia activated prodrugs |
| 08/03/2011 | EP2350656A1 Methods and kits to identify invasive glioblastoma |
| 08/03/2011 | EP2350642A1 Na/k-atpase expression as an indicator for the treatment of cancer |
| 08/03/2011 | EP2350641A1 Method of treatment |
| 08/03/2011 | EP2350282A1 Increased expression of specific antigens |
| 08/03/2011 | EP2350276A1 Syngr4 for target genes of cancer therapy and diagnosis |
| 08/03/2011 | EP2350273A2 Compositions of engineered human arginases and methods for treating cancer |
| 08/03/2011 | EP2350131A2 Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling |
| 08/03/2011 | EP2350115A1 Antimicrobial compounds |
| 08/03/2011 | EP2350095A1 Fused ring thiophene dyes for imaging and therapy |
| 08/03/2011 | EP2350087A1 Regioselective reduction of fused pyrrolocarbazoles-5,7-diones |
| 08/03/2011 | EP2350086A2 Fused diimidazodiazepine compounds and methods of use and manufacture thereof |
| 08/03/2011 | EP2350085A1 Quinazolinone linked pyrroloý2,1 -c¨ý1.4¨benzodiazepine hybrids as potential anticancer agents and process forthe preparation thereof |
| 08/03/2011 | EP2350084A1 Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |